Doximity Stock Declines Amid Software Stock Bust
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Source: NASDAQ.COM
Doximity's stock has plummeted 6.69% as it crosses below the 5-day SMA, reflecting broader market weakness with the Nasdaq-100 down 1.36% and S&P 500 down 1.11%.
The decline is attributed to the ongoing software stock bust, where Doximity's stock has fallen 66% during this period, trading near all-time lows despite its strong profitability and solid customer base. Concerns about future prospects have overshadowed its impressive revenue growth of 448% since March 2020, with the latest quarter showing only 10% year-over-year growth, indicating potential for further expansion within its existing medical marketing tools.
Despite the current market conditions, Doximity maintains a strong EBIT margin of 38.5%, positioning it as a best-in-class software provider. Investors may find value in its price-to-earnings ratio of 21, suggesting potential growth opportunities amidst the AI-induced market dip.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise
18 Analyst Rating
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 20.450
Low
25.00
Averages
42.75
High
63.00
Current: 20.450
Low
25.00
Averages
42.75
High
63.00
About DOCS
Doximity, Inc. operates as a digital platform for United States medical professionals. The Company provides an online platform which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers primarily include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Its marketing solutions provide customers to share content on the network. Its hiring solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates. Its Workflow solutions allow customers to initiate voice and video calls with patients and manage on-call scheduling.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Doximity Under Investigation Amid 23% Stock Drop Following Earnings Miss
- Disappointing Financial Results: Doximity's Q4 and fiscal year 2026 earnings report revealed a revenue guidance of $664 million to $676 million, falling short of the $687.04 million estimate, indicating significant revenue pressure on the company.
- AI Cost Pressures: Management highlighted that AI compute costs negatively impacted gross margins, with CEO Jeff Tangney warning that increased investment in AI will weigh on near-term profitability, reflecting challenges in technology investments.
- Stock Price Volatility: Following the earnings report, Doximity's stock price plummeted by $5.38, or 23%, closing at $18.01 per share on May 14, 2026, indicating market concerns about the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating claims against Doximity and its executives for potential securities fraud or other unlawful business practices, advising investors to contact the firm for more information, which may lead to further legal risks.
See More
Doximity Under Investigation as Shares Plunge 23%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Doximity, focusing on potential violations of securities laws regarding false or misleading statements, indicating serious legal risks for the company that could impact investor rights.
- Earnings Miss Expectations: Doximity's financial results released on May 13, 2026, revealed that full-year revenue fell short of consensus estimates, reflecting competitive pressures that may undermine future investor confidence in the company.
- CEO Warns of Margin Pressure: The CEO indicated that increased investments in AI will negatively impact near-term margins, raising investor concerns about the company's future profitability and further affecting stock performance.
- Stock Price Volatility: Following these announcements, Doximity's shares plummeted by 23% the next day, reflecting a pessimistic outlook from the market regarding the company's future, potentially prompting more investors to seek legal recourse to protect their interests.
See More
Doximity Faces Securities Fraud Investigation
- Financial Performance Warning: Doximity's Q4 2026 financial report projects full-year revenue between $664 million and $676 million, falling short of market expectations of $687.04 million, indicating significant financial pressure on the company.
- AI Cost Pressures: Management highlighted that AI compute costs are negatively impacting gross margins, with CEO Jeff Tangney warning that increased AI investments will weigh on near-term profits, potentially undermining investor confidence.
- Stock Price Plunge: Following the earnings report, Doximity's stock price plummeted by $5.38, or 23%, closing at $18.01 per share on May 14, 2026, reflecting market concerns about the company's outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating Doximity and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action lawsuit.
See More
Doximity Investment Opportunities Explored
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, analysts discussed market trends surrounding Doximity, noting that while it did not make the list of the top 10 recommended stocks, it still provides valuable investment insights, reflecting market interest in its future potential.
- Return Comparison: The Motley Fool Stock Advisor boasts an average return of 984%, significantly outperforming the S&P 500's 210%, indicating that even though Doximity is not recommended, investors should still monitor its potential market performance.
- AI and Technology Dependency: The episode highlighted that Doximity could benefit from advancements in AI technology, particularly through partnerships with key tech companies like Nvidia and Intel, which may drive future growth, although it is not currently on the recommended list.
- Investor Community Engagement: Motley Fool encourages investors to join its community for the latest investment advice and market analysis; while Doximity is not on the recommendation list, its market performance remains noteworthy, and investors should stay vigilant.
See More
Doximity Market Trends Analysis
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, expert analysts discuss market trends related to Doximity, providing deep insights into investment opportunities that help investors better understand industry dynamics.
- Investment Opportunity Assessment: The episode notes that Doximity's stock price was $4.05 on April 8, 2026, reflecting market interest in the company, which may attract more investors.
- Expert Opinions Shared: Through the video content, analysts share their views on Doximity's future development, emphasizing its potential growth in the healthcare sector, which could influence investor decisions.
- Industry Dynamics Analysis: The program also covers overall trends in the healthcare industry, with analysts pointing out that Doximity's innovations in digital healthcare may drive an increase in its market share, enhancing its competitiveness.
See More
Doximity Shares Plunge 56% Amid AI Threat Concerns
- Stock Decline: Doximity's shares have plummeted 56% following its fourth-quarter earnings report in 2026, highlighting market concerns regarding the company's ability to survive the threats posed by the rise of AI technologies.
- Strong User Base: With over 85% of U.S. physicians using its platform, Doximity has established a massive network that attracts all of the top 20 pharmaceutical companies as advertising clients, underscoring its solid market position.
- AI Tool Adoption: In the fourth quarter, approximately 50% of Doximity's 800,000 active prescribers utilized AI tools within its workflow solutions, indicating the company's proactive integration of AI despite competitive pressures in the market.
- Optimistic Investment Outlook: Despite rising costs during its
See More
Doximity Under Investigation Amid 23% Stock Drop Following Earnings Miss
- Disappointing Financial Results: Doximity's Q4 and fiscal year 2026 earnings report revealed a revenue guidance of $664 million to $676 million, falling short of the $687.04 million estimate, indicating significant revenue pressure on the company.
- AI Cost Pressures: Management highlighted that AI compute costs negatively impacted gross margins, with CEO Jeff Tangney warning that increased investment in AI will weigh on near-term profitability, reflecting challenges in technology investments.
- Stock Price Volatility: Following the earnings report, Doximity's stock price plummeted by $5.38, or 23%, closing at $18.01 per share on May 14, 2026, indicating market concerns about the company's future outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating claims against Doximity and its executives for potential securities fraud or other unlawful business practices, advising investors to contact the firm for more information, which may lead to further legal risks.
See More
Doximity Under Investigation as Shares Plunge 23%
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Doximity, focusing on potential violations of securities laws regarding false or misleading statements, indicating serious legal risks for the company that could impact investor rights.
- Earnings Miss Expectations: Doximity's financial results released on May 13, 2026, revealed that full-year revenue fell short of consensus estimates, reflecting competitive pressures that may undermine future investor confidence in the company.
- CEO Warns of Margin Pressure: The CEO indicated that increased investments in AI will negatively impact near-term margins, raising investor concerns about the company's future profitability and further affecting stock performance.
- Stock Price Volatility: Following these announcements, Doximity's shares plummeted by 23% the next day, reflecting a pessimistic outlook from the market regarding the company's future, potentially prompting more investors to seek legal recourse to protect their interests.
See More
Doximity Faces Securities Fraud Investigation
- Financial Performance Warning: Doximity's Q4 2026 financial report projects full-year revenue between $664 million and $676 million, falling short of market expectations of $687.04 million, indicating significant financial pressure on the company.
- AI Cost Pressures: Management highlighted that AI compute costs are negatively impacting gross margins, with CEO Jeff Tangney warning that increased AI investments will weigh on near-term profits, potentially undermining investor confidence.
- Stock Price Plunge: Following the earnings report, Doximity's stock price plummeted by $5.38, or 23%, closing at $18.01 per share on May 14, 2026, reflecting market concerns about the company's outlook.
- Legal Investigation Initiated: Pomerantz LLP is investigating Doximity and its executives for securities fraud and other unlawful business practices, advising investors to contact the firm for information on joining the class action lawsuit.
See More
Doximity Investment Opportunities Explored
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, analysts discussed market trends surrounding Doximity, noting that while it did not make the list of the top 10 recommended stocks, it still provides valuable investment insights, reflecting market interest in its future potential.
- Return Comparison: The Motley Fool Stock Advisor boasts an average return of 984%, significantly outperforming the S&P 500's 210%, indicating that even though Doximity is not recommended, investors should still monitor its potential market performance.
- AI and Technology Dependency: The episode highlighted that Doximity could benefit from advancements in AI technology, particularly through partnerships with key tech companies like Nvidia and Intel, which may drive future growth, although it is not currently on the recommended list.
- Investor Community Engagement: Motley Fool encourages investors to join its community for the latest investment advice and market analysis; while Doximity is not on the recommendation list, its market performance remains noteworthy, and investors should stay vigilant.
See More
Doximity Market Trends Analysis
- Market Trend Insights: In the latest Motley Fool Scoreboard episode, expert analysts discuss market trends related to Doximity, providing deep insights into investment opportunities that help investors better understand industry dynamics.
- Investment Opportunity Assessment: The episode notes that Doximity's stock price was $4.05 on April 8, 2026, reflecting market interest in the company, which may attract more investors.
- Expert Opinions Shared: Through the video content, analysts share their views on Doximity's future development, emphasizing its potential growth in the healthcare sector, which could influence investor decisions.
- Industry Dynamics Analysis: The program also covers overall trends in the healthcare industry, with analysts pointing out that Doximity's innovations in digital healthcare may drive an increase in its market share, enhancing its competitiveness.
See More
Doximity Shares Plunge 56% Amid AI Threat Concerns
- Stock Decline: Doximity's shares have plummeted 56% following its fourth-quarter earnings report in 2026, highlighting market concerns regarding the company's ability to survive the threats posed by the rise of AI technologies.
- Strong User Base: With over 85% of U.S. physicians using its platform, Doximity has established a massive network that attracts all of the top 20 pharmaceutical companies as advertising clients, underscoring its solid market position.
- AI Tool Adoption: In the fourth quarter, approximately 50% of Doximity's 800,000 active prescribers utilized AI tools within its workflow solutions, indicating the company's proactive integration of AI despite competitive pressures in the market.
- Optimistic Investment Outlook: Despite rising costs during its
See More
